4-Phenylhydrazo-5-pyrazolon | 53847-69-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Phenylhydrazo-5-pyrazolon
• 英文别名: 2H-pyrazole-3,4-dione 4-phenylhydrazone；2H-Pyrazol-3,4-dion-4-phenylhydrazon；4-(2-phenylhydrazinyl)pyrazol-3-one
• CAS: 53847-69-1
• 化学式: C₉H₈N₄O
• 分子量: 188.189
• InChiKey: JUIQIRLXPMKPEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  氯化重氮苯 、 alkaline earth salt of/the/ methylsulfuric acid 在 氢氧化钾 作用下， 生成 4-Phenylhydrazo-5-pyrazolon
  参考文献：
  名称：

  Religion, Death of a Loved One, and Hypertension Among Older Adults in Japan

  摘要：

  Objective. To see whether three dimensions of religion (private religious practices, religious coping, and belief in the hypertension over time. afterlife) buffer the effect of the death of a significant other on change in self-reportedMethods. Interviews were conducted with a nationally representative sample of people aged 60 and older in Japan at two points in time. 1996 and 1999. Complete data were available on 1,723 older Japanese, Respondents were asked a series of questions about their religious beliefs and practices, A bother a family member or close friend had died in the past year, and whether they had hypertension.Results. The data suggest that older adults in Japan who experienced the death of a loved one but who believed in a good afterlife were less likely to report they had hypertension at the follow-up interview than elderly people in Japan who lost a close other but did not believe in a good afterlife.Discussion. The results suggest how one overlooked dimension of religion (i.e.. religious beliefs) may bolster the health of older people in the face of adversity.

  DOI：

  10.1093/geronb/57.2.s96

文献信息

• [EN] HYDRAZONOPYRAZOLONES AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS<br/>[FR] HYDRAZONOPYRAZOLONES COMME INHIBITEURS DE LA PROTÉINE TYROSINE PHOSPHATASE
  申请人：MAX DELBRUECK CENTRUM

  公开号：WO2012041524A1

  公开（公告）日：2012-04-05

  This invention relates to novel compounds useful in inhibiting protein tyrosine phosphatase activity, especially' Shp2 protein tyrosine phosphatase activity, pharmaceutical compositions comprising at least one of said compounds and their use for treating phosphatase-mediated diseases, especially Shp2- mediated diseases. These compounds act as protein tyrosine phosphatase (FTP) inhibitors, preferably as selective Shp2 inhibitors, and can therefore be used for the treatment of conditions, where protein tyrosine phosphatases are implicated, including cardiovascular, immunological, infectious, neurological, metabolic diseases, and cancer. Compounds of the invention are also useful as research tools for investigating the role of PTPs in signal transduction.